Noida, UP -- (SBWIRE) -- 06/30/2015 -- Pfizer is the major player accounting for 76% of the total market in value and 71% in volume in 2014. Its product potfolio for Pneumonia vaccine consists of Prevnar 13/Prevenar 13 and Prevenar (7-valent), collectively known as the Prevnar family. The family witnessed an increase of 14% in the operational revenue in 2014. In the US, revenues for Prevnar 13 increased 19% in 2014 mainly due to government purchasing patterns and price increases, and increased demand, primarily driven by additional market penetration of Prevnar 13 in adults.

Research Analysis & Highlights

According to our report, "Global Pneumonia Vaccine Market Outlook 2020", the Pneumonia vaccine market for 2014, which has been estimated at US$ 5.9 Billion is expected to reach US$ 11 Billion by 2020, growing at a CAGR of 11.1% over the six year period. The report offers a clear and succinct take on the current Pneumococcal Vaccine Industry. The regional distribution of the current market has also been discussed.

As vaccines are highly regulated to ensure patients and users have access to safe and effective medicines, the regulatory scenarios for vaccine approval and licensing has also been discussed. It has been noted that individual governments determine which products can be marketed in their countries and many have state-regulated systems governing product pricing.

Lastly, the report talks of the three major players of the industry; GlaxoSmithKline, Pfizer and Merck. The competitive landscape is supplemented with a chapter highlghting the current share of every player in the market. This is followed by company profiles, wherein the general business alongwith the key finanacials of every player have been provided. At the end of every profile, a strength weakness analysis has been performed. The report provides a prudent analysis of the market and is a must have supplement for any player interested in the industry.

Some of the key highlights of the report include:

- Pneumococcal Vaccine Industry to Grow to US$ 11 Billion by 2020
- Developing Regions to Capture a major chunk of the Pneumococcal Vaccine Industry in the Future

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM764.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.